As of January 22, 2025, Tourmaline Bio (TRML) has a market cap of $0.45 billion USD. According to our data, Tourmaline Bio is ranked No.6245 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.45 B |
-13.02%
|
Dec 31, 2024 | $0.52 B |
-22.54%
|
Dec 29, 2023 | $0.67 B |
477.83%
|
Dec 30, 2022 | $0.12 B |
-93.33%
|
Dec 31, 2021 | $1.74 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
BioMarin Pharmaceutical
BMRN
|
$11.82 B |
0.000 M
|
USA
|
Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
Incyte
INCY
|
$13.95 B |
-0.000 M
|
USA
|
Ionis Pharmaceuticals
IONS
|
$5.13 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Market Cap | = | TRML Stock Price | * | TRML Shares Outstanding |
= | $17.64 | * | 25.64 M | |
= | $0.45 B |